Inclusion Criteria:

- Female patients, >/= 18 years of age

- HER2-positive breast cancer

- No evidence of residual, locally recurrent or metastatic disease after completion of
surgery and chemotherapy (neoadjuvant or adjuvant)

- All adjuvant chemotherapy must be completed, adjuvant radiotherapy may be ongoing

- Patients who have already received IV Herceptin must have at least 10 out of the
total planned 18 3-week cycles remaining

- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

Exclusion Criteria:

- History of other malignancy, except for ductal carcinoma in situ of the breast,
curatively treated carcinoma in situ of the cervix or basal cell carcinoma, or other
curatively treated malignancies that have been disease-free for at least 5 years

- Inadequate bone marrow function

- Impaired liver function

- Inadequate renal function

- Serious cardio-vascular disease

- HIV or hepatitis B (HBV) or C (HCV) infection

- Prior maximum cumulative dose of doxorubicin > 360 mg/m2 or epirubicin > 720 mg/m2 or
equivalent